Pre-earnings options volume in Pac Bio is normal with calls leading puts 26:1. Implied volatility suggests the market is anticipating a move near 15.5%, or 23c, after results are released. Median move over the past eight quarters is 7.6%.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio Revio HiFi sequencing system chosen for Singapore health project
- Singapore’s National Precision Medicine (NPM) programme will partner with PacBio to propel HiFi Sequencing in Southeast Asia
- PACB Upcoming Earnings Report: What to Expect?
- PacBio announces Novogene is using its Revio
- Novogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing